NCT02696291 - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

March 2, 2017

Study Completion Date

March 2, 2017

Conditions

Viral Infection

Interventions

DRUG

UV-4B 30 mg oral solution

UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

DRUG

UV-4B 75 mg oral solution

UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

DRUG

UV-4B 150 mg oral solution

UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

DRUG

UV-4B X mg (dose to be determined) oral solution

UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

DRUG

UV-4B Y mg (dose to be determined) oral solution

UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

DRUG

Placebo

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Trial Locations (2)

Clinical Research Unit, Madison

Clinical Research Unit, Dallas